Shareholders of Neumora Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - NMRA

Core Viewpoint - Neumora Therapeutics, Inc. is facing a class action securities lawsuit due to alleged securities fraud affecting investors who purchased its common stock since September 15, 2023 [1][2]. Class Definition - The lawsuit aims to recover losses for all individuals or entities that acquired Neumora common stock based on the Offering Documents [2]. Case Details - The complaint alleges that Neumora made false statements and concealed critical information regarding its Phase Three Program and Phase Two Trials, including: 1. Amendments to the original Phase Two trial inclusion criteria to include patients with moderate to severe Major Depressive Disorder (MDD) to demonstrate the efficacy of Navacaprant [3]. 2. Addition of a prespecified analysis in the Phase Two statistical analysis plan focusing on moderate to severe MDD patients [3]. 3. Insufficient data in the Phase Two Trials, particularly regarding patient population size and gender ratio, which undermined the ability to predict outcomes of the KOASTAL-1 study [3]. Next Steps - Investors who suffered losses during the relevant timeframe have until April 7, 2025, to request appointment as lead plaintiff, although participation does not require this role [4]. No Cost to Participants - Class members may be entitled to compensation without any out-of-pocket costs or fees, and there is no obligation to participate [4]. Why Levi & Korsinsky - The firm has a strong track record in securities litigation, having secured hundreds of millions for shareholders and consistently ranking among the top securities litigation firms in the U.S. [5].